Crowley Wealth Management Inc. Purchases Shares of 2,480 Gilead Sciences, Inc. (NASDAQ:GILD)

Crowley Wealth Management Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,480 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Napatree Capital LLC lifted its position in shares of Gilead Sciences by 18.5% in the fourth quarter. Napatree Capital LLC now owns 6,220 shares of the biopharmaceutical company’s stock worth $575,000 after purchasing an additional 971 shares in the last quarter. LPL Financial LLC grew its stake in shares of Gilead Sciences by 6.1% in the fourth quarter. LPL Financial LLC now owns 1,206,472 shares of the biopharmaceutical company’s stock valued at $111,442,000 after acquiring an additional 69,091 shares in the last quarter. Blueprint Investment Partners LLC raised its stake in Gilead Sciences by 59.9% in the 4th quarter. Blueprint Investment Partners LLC now owns 6,771 shares of the biopharmaceutical company’s stock worth $625,000 after purchasing an additional 2,537 shares in the last quarter. Mosley Wealth Management boosted its holdings in Gilead Sciences by 5.8% in the 4th quarter. Mosley Wealth Management now owns 5,772 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 319 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $524,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 over the last ninety days. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $107.08 on Friday. The stock has a market capitalization of $133.35 billion, a P/E ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The business has a 50 day simple moving average of $103.68 and a two-hundred day simple moving average of $93.85.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Analyst Ratings Changes

Several equities analysts have commented on GILD shares. BMO Capital Markets raised their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Oppenheimer lifted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.